Although Atlassian's fiscal Q3 revenue and earnings upside "was solid," billings were below consensus, Mizuho analyst Gregg Moskowitz tells investors in a post-earnings research note. However, his work indicates a "high likelihood" that this is solely a function of a greater than expected pull forward impact in fiscal Q2. Normalizing for this, the analyst estimates "very healthy" fiscal Q3 billings growth in the high 30% range. Moskowitz remains buying the shares, "especially on any significant weakness." He keeps a Buy rating on Atlassian with a $125 price target.